- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00242164
Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Heart disease is a major cause of illness and death among patients on dialysis. Changes in the heart's rhythm and sudden cardiac death are also important problems in this group. Abnormal rhythm can occur during hemodialysis.
During dialysis, the blood comes in contact with a solution called dialysate. This solution contains minerals like calcium, potassium and magnesium. Some studies have indirectly suggested that lower magnesium in dialysis patients protects them from having rhythm problems.
Factors that increase the chance for the development of abnormal rhythms can be indirectly assessed by evaluating the electrocardiogram (EKG). This is done by measuring the distance between the wave forms on the EKG. One of these is called the QT interval. QT dispersion is a value derived from the QT interval. A long QT interval is thought to make an individual more prone to having abnormal heart rhythms.
Therefore it is planned to study the effect of low levels of magnesium in the dialysate on QT interval and dispersion and the tendency for rhythm change. QT interval changes will be compared during dialysis with low magnesium with QT interval changes during dialysis with normal magnesium.
This will be a cross over trial including 24 adult male and female patients on chronic hemodialysis. Subjects will be studied during two of their regular dialysis sessions, the only difference being the amount of magnesium in the dialysate. QT interval and QT dispersion will be calculated from the EKG recordings before and after each dialysis session.
The results of this study will lead to a better understanding of cardiovascular risks in patients undergoing chronic dialysis and may offer a potentially novel strategy to reduce the risk of abnormal heart rhythms risk during dialysis.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48104
- University of Michigan Dialysis Center
-
Livonia, Michigan, Förenta staterna, 48152
- University of Michigan Dialysis Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18 years of age and over with end-stage renal disease. (ESRD)
- have been on maintenance hemodialysis therapy three times/week for greater than or equal to 3 months
- All causes of renal failure are included
Exclusion Criteria:
- less than 18 years of age
- have been on maintenance hemodialysis therapy three times/week for less than 3 months
- are pregnant or lactating
- unable or unwilling to provide informed consent
- currently participating in a clinical trial with an intervention
- systolic (top number) blood pressure levels greater than or equal to 180 or less then 80
- diastolic (bottom number) blood pressure levels greater than 110
- a hemoglobin level (red blood cell measure) that is less than 8mg/dl
- a corrected calcium level that is greater than 11mg/dl or less than 8mg/dl
- had a change in their anti-hypertensive medications within the last three weeks
- clinical signs and symptoms of untreated or unresolved infection
- clinical evidence requiring admission to the hospital
- had a cerebral vascular accident or myocardial incident within the past 3 months
- Based on the assessment of the investigators, or study coordinator designee, patients who appear unlikely or unable to participate in the required study procedures
- Patients with a history of arrhythmias, recent electrophysiological evaluation and or having pacemakers are excluded.
- Patients with acute renal failure.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The primary outcome is the difference in QT dispersion between low dialysate magnesium and normal dialysate magnesium
Tidsram: over one dialysis session
|
measurement will be the duration of some changes in the EKG.
|
over one dialysis session
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Panduranga S Rao, MD, DNB, MS, University of Michigan
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DRDA 05-2076
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk njursjukdom
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
Medical University of ViennaAvslutadSekundär hyperparatyreos | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NjurersättningÖsterrike
-
Alcon ResearchAvslutad
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekryteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Dhulikhel HospitalKathmandu University School of Medical SciencesIndragenPostoperativ analgesi | CSOM - Chronic Suppurative Otitis MediaNepal
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgAvslutadLimbal stamcellsbrist | Hornhinnas sjukdom | Eyes Dry Chronic | Kronisk konjunktivit i båda ögonen | Ögonskada | Ögonsjukdom; Grå starr | Ögon torr känsla av | Hornhinnan inflammerad | Hornhinna; Skada, nötning | Hornhinna infektionÖsterrike
-
Detroit Clinical Research CenterIpsenOkändTourettes syndrom | Chronic Vocal TicFörenta staterna
-
AstraZenecaCLL ConsortiumAvslutadB-cellslymfom | 11q-deleted Relapsed/Refractory Chronic Lymfocytic Leukemi (KLL), | Prolymfocytisk leukemi (PLL)Förenta staterna
-
Boston Scientific CorporationAvslutadVasovagal synkope | Arytmi | Atrioventrikulärt hjärtblock | Chronic Bundle Branch eller Branch Block | Carotid sinus överkänslighetsreaktionssyndromKina
Kliniska prövningar på Dialysate Magnesium (Concentration)
-
Iain BressendorffAvslutadNjursjukdom i slutskedetDanmark
-
National University Hospital, SingaporeNational University of SingaporeAvslutadHypotoni | Dialys AmyloidosSingapore
-
Istituto Clinico HumanitasOkändKnäartros | BroskdegenerationItalien
-
University Hospital, MontpellierRekryteringAkut njurskada | NjurersättningsterapiFrankrike
-
Alexandria UniversityHar inte rekryterat ännuDialys; KomplikationerEgypten
-
Shanghai Jiao Tong University School of MedicineAvslutadNjursjukdom i slutskedetKina
-
Ege UniversityFresenius Medical Care North AmericaAvslutadHemodialys | Njursjukdom i slutskedetKalkon
-
Centre Hospitalier de BethuneCHU de LilleRekrytering
-
Sir Charles Gairdner HospitalOkändKroniska njursjukdomar | Njursjukdom i slutskedet | Dialysrelaterade komplikationer
-
Zydus Therapeutics Inc.UpphängdDyslipidemierFörenta staterna